Speakers

Expand/Collapse

Poul Sørensen
Professor, Chief Scientific Officer & Co-Founder
Allero Therapeutics

Day Two

Thursday – January 27, 2022

10:00 am | Harnessing the Oral Mucosa for Antigen-Specific Immunotherapy of Immune Disorders

Andreas Lutterotti
Chief Medical Officer
Cellerys

Day Two

Thursday – January 27, 2022

3:00 pm | Establishing Immune Tolerance in Multiple Sclerosis Using Peptide-Coupled Red Blood Cells

Matthias von Herrath
Vice President & Senior Medical Officer, Global Chief Medical Officer
Novo Nordisk

Day One

Wednesday – January 26, 2022

2:00 pm | The Struggles with Immune Biomarkers and Pathologic Endotypes in Type 1 Diabetes

Charlotte Fribert
Chief Executive Officer
Toleranzia

Day Two

Thursday – January 27, 2022

9:30 am | Large Molecule Drug Development for the Treatment of Myasthenia Gravis

Evelien Schurgers
Associate Director Research
WORG Pharmaceuticals

Day Two

Thursday – January 27, 2022

2:30 pm | Antigen-Specific Immunotherapy with Thyrotropin Receptor Peptides in Graves’ Hyperthyroidism

Jessica Grossman
Chief Executive Officer
IgGenix, Inc

Day One

Wednesday – January 26, 2022

9:00 am | SWOT Analysis-Style Panel Discussion - Topics to be Addressed:

Vincent Carlier
Immunology Director
Imcyse

Day One

Wednesday – January 26, 2022

12:00 pm | Understanding the Mechanism of Action of Imotopes™ at Molecular and Cellular Level

James Moon
Co-Founder & Chief Scientific Officer; Professor of Pharmaceutical Sciences
EVOQ Therapeutics; University of Michigan

Day Two

Thursday – January 27, 2022

12:30 pm | A Novel NanoDisc Platform for Systemic Targeting of Lymphoid Tissues and Induction of Antigen-Specific Immune Tolerance

Asa Schott
Chief Scientific Officer
Idogen AB

Day Two

Thursday – January 27, 2022

11:30 am | A Novel Tolerogenic Dendritic Cell Platform with the Potential to Present the Antigen FVIII to Induce Tolerance Against FVIII in Haemophilia A Patients

Bryan Vander Lugt
Senior Scientist
Amgen

Day One

Wednesday – January 26, 2022

9:00 am | SWOT Analysis-Style Panel Discussion - Topics to be Addressed:

8:50 am | Chair’s Opening Remarks

David Wraith
Founder & Chief Scientific Officer; Director, Institute of Immunology & Immunotherapy
Apitope; University of Birmingham

Day One

Wednesday – January 26, 2022

9:00 am | SWOT Analysis-Style Panel Discussion - Topics to be Addressed:

Remi J. Creusot
Assistant Professor of Medical Sciences
Columbia University

Day One

Wednesday – January 26, 2022

11:30 am | Strategies for Epitope-Based Tolerance-Inducing Immunotherapy

Adam Elhofy
Director of Immunology
COUR Pharmaceuticals

Day One

Wednesday – January 26, 2022

3:30 pm | Antigen-Specific Tolerance to Multiple Epitopes in T1D

Ulf Hannelius
President & Chief Executive Officer
Diamyd Medical

Day One

Wednesday – January 26, 2022

4:00 pm | Precision Medicine and Antigens – The Case of HLA and GADSpecific Immunotherapy in Type 1 Diabetes

Klaus Ley
Professor/Division Head - Center for Autoimmunity & Inflammation
La Jolla Institute for Immunology

Day One

Wednesday – January 26, 2022

10:00 am | Inducing Tolerance to ApoB Epitopes to Curb Atherosclerosis

Wanjun Chen
Senior Investigator & Chief, Mucosal Immunology Section
NIDCR, NIH

Day One

Wednesday – January 26, 2022

9:30 am | Manipulation of TGF-β for Antigen-Specific Immunotherapy of Autoimmune Diseases

Stephen D. Miller
Judy Gugenheim Research Professor, Department of Microbiology- Immunology
Northwestern University Feinberg School of Medicine

Day One

Wednesday – January 26, 2022

2:30 pm | Requirement for Induced Tregs and Tr1 Cells or Regulation of Autoimmune Disease Using Antigen Encapsulating PLG Nanoparticles

Aaron Winkler
Research Fellow, Immune Tolerance Lead, Inflammation & Immunology
Pfizer, Inc.

Day Two

Thursday – January 27, 2022

8:50 am | Chair’s Opening Remarks

Klaus Martin
Chief Executive Officer
Topas Therapeutics

Day Two

Thursday – January 27, 2022

2:00 pm | A Nanoparticle Platform for Multiple Immune Tolerance Therapies

Rainer Henning
Chief Scientific Officer
WORG Pharmaceuticals

Day Two

Thursday – January 27, 2022

12:00 pm | The PCFiT Platform: A Promising Approach for B-Cell Directed Allergy Immunotherapy

Michael Yeaman
Professor of Medicine, Chief, Molecular Medicine, Director, Institute for Infection & Immunity; Lundquist Institute; Chair, Medical Sciences, Guthy-Jackson Charitable Foundation
UCLA

Day Two

Thursday – January 27, 2022

9:00 am | Facilitating Translation of Tolerization Technologies

Daniel Rotrosen
Director, Division of Allergy, Immunology & Transplantation
National Institute of Allergy & Infectious Diseases of Allergy & Infectious Diseases

Day One

Wednesday – January 26, 2022

12:30 pm | NIAID Funding Mechanisms for Immune Tolerance Research